Clinical Trials
15 trialsNCT07551414 2026-04-24
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05805631 2026-03-24
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
Phase 2 Recruiting
NCT06296745 2026-01-30
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Guangzhou Medical University
Phase 2 Recruiting
NCT07304739 2025-12-26
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06518057 2025-12-11
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
Phase 2 Recruiting
NCT06910761 2025-12-08
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06971406 2025-05-14
FLAME-1
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06728865 2024-12-11
Better Brain
Sun Yat-sen University
Phase 2 Recruiting
NCT05813522 2023-04-14
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05810350 2023-04-13
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Three Gorges Hospital of Chongqing University
Phase 2 Unknown
NCT02616393 2022-03-16
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Phase 2 Completed
NCT04833205 2021-04-20
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Hebei Medical University
Phase 2 Unknown
NCT04425681 2020-06-11
OWBLM
Second Affiliated Hospital of Nanchang University
Phase 2 Unknown
NCT04148898 2019-11-04
OWONBNSCLCLM
Second Affiliated Hospital of Nanchang University
Phase 2 Unknown
NCT00830245 2011-07-26
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea
Phase 2 Terminated